An incident occurred in the Oval Office today where a pharmaceutical executive collapsed during a press conference, contrary to earlier misinformation regarding the individual’s identity. The man, who remains unidentified, was positioned behind the US president as the Trump administration unveiled a new agreement concerning weight-loss medications. Suddenly, his knees gave way, causing him to collapse.
Upon witnessing the episode, administration officials and representatives from the pharmaceutical industry swiftly rushed to his aid to prevent any injury. White House Press Secretary Karoline Leavitt clarified that during the ‘Most Favored Nations Oval Office Announcement,’ a representative from one of the companies experienced a fainting spell.
Assuring that the individual received prompt medical attention and was ultimately deemed to be in good condition, Leavitt announced that the press conference would resume shortly. She reiterated the incident in an official statement, stating, “During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted. The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly.”
Following the incident, reporters were escorted out of the Oval Office as cabinet members tended to the collapsed individual by elevating his legs. The exact cause of the collapse remains undisclosed.
The press conference featured executives from pharmaceutical giants Novo Nordisk and Eli Lilly alongside the Trump administration, revealing a groundbreaking deal that could have significant implications for the healthcare sector. As per the plan, the manufacturers of Ozempic, Wegovy, and Zepbound will directly offer their treatments to the public through TrumpRx, a forthcoming government website. The companies have pledged that an oral version of the medications may be available for as low as $149 (£113) per month upon FDA approval. Additionally, individuals under Medicare or Medicaid with diabetes and other approved conditions can expect a reduced monthly cost of $245 (£186) for the injectable versions.
Receive email updates featuring the day’s top stories.